IELSG32 - Randomised phase II trial on initial therapy with high-dose methotrexdate and high-dose cytarabine with or without thiotepa and/or rituximab, followed by brain irradiation vs. autologous stem cells transplantation for primary CNS lymphoma
People
(Responsible)
Additional information
Acronym
IELSG32
Start date
01.01.2011
End date
01.01.2014
Duration
36 Months
Funding sources
SNSF
Status
Ended
Category
Swiss National Science Foundation /
Project Funding /
Life Sciences (Division III)
